8月7日，药捷安康-B盘中上涨21.51%，报14.04港元，成交额2036.61万港元。
消息面上，公司8月6日公告，自主研发的1类新药捷恩泰®（替恩戈替尼片）获国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者治疗。该产品此前已被NMPA纳入优先审评及突破性治疗品种，本次获批基于一项在中国开展的多中心、开放性、单臂II期关键性临床试验。此外，替恩戈替尼全球注册性III期临床试验已于7月完成入组，商业化前景进一步明朗。本次获批标志着公司从研发阶段正式迈入商业化阶段。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.